Cognitive functions over the course of 1 year in multiple sclerosis patients treated with disease modifying therapies
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Therapeutic Advances in Neurological Disorders 9.4 (2016): S. 269-280.
- Keyword
-
-
Hirnkrankheit
Neuropsychiatrie
Nervenkrankheit
- Event
-
Veröffentlichung
- (where)
-
Erlangen
- (who)
-
Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
- (when)
-
2016
- Creator
-
Utz, Kathrin S.
Lee, De-Hyung
Lämmer, Alexandra
Waschbisch, Anne
Linker, Ralf A.
Schenk, Thomas
- URN
-
urn:nbn:de:bvb:29-opus4-90485
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:47 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Utz, Kathrin S.
- Lee, De-Hyung
- Lämmer, Alexandra
- Waschbisch, Anne
- Linker, Ralf A.
- Schenk, Thomas
- Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
Time of origin
- 2016
Other Objects (12)
Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions
Evaluation and further development of handbooks explaining different disease-modifying therapies for people with multiple sclerosis (MS)
Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis: a review of population-specific evidence from randomized clinical trials
Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets
Studies on pathomechanisms and novel therapies in amyotrophic lateral sclerosis
Early spinal cord pseudoatrophy in interferon‐beta‐treated multiple sclerosis
Modifying adjuncts
Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists
Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis
Medication beliefs in first-line and second-line treated multiple sclerosis patients
Modifying branched surfaces
Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions
Evaluation and further development of handbooks explaining different disease-modifying therapies for people with multiple sclerosis (MS)
Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis: a review of population-specific evidence from randomized clinical trials
Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets
Studies on pathomechanisms and novel therapies in amyotrophic lateral sclerosis
Early spinal cord pseudoatrophy in interferon‐beta‐treated multiple sclerosis
Modifying adjuncts
Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists
Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis
Medication beliefs in first-line and second-line treated multiple sclerosis patients
Modifying branched surfaces
Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions
Evaluation and further development of handbooks explaining different disease-modifying therapies for people with multiple sclerosis (MS)
Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis: a review of population-specific evidence from randomized clinical trials
Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets
Studies on pathomechanisms and novel therapies in amyotrophic lateral sclerosis
Early spinal cord pseudoatrophy in interferon‐beta‐treated multiple sclerosis
Modifying adjuncts
Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists
Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis
Medication beliefs in first-line and second-line treated multiple sclerosis patients